Published by Benjamin Chiou on 14th May 2025
(Sharecast News) - GSK announced on Wednesday that it has entered into an agreement with Boston Pharmaceuticals to acquire its lead asset Efimosfermin for up to $2bn, buying a specialty medicine to treat and prevent progression of steatotic liver disease (SLD).
URL: http://www.digitallook.com/dl/news/story/35078810/...